Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Only four months after it was carved out from Sanofi to become an independent company, Prague-based Zentiva has announced fresh leadership in the form of Nick Haggar, the 30-year industry veteran and former president of Medicines of Europe.
A month after a court ruled that Fresenius Kabi’s decision to terminate its merger with Akorn was legal and proper, Akorn’s COO has agreed to resign the position, six days after Doug Boothe officially replaced Raj Rai as Akorn’s new president and CEO.
The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.
Around two weeks after announcing that the firm was seeking a new CEO, Akorn has chosen former president of Impax’ generics division, Doug Boothe, to lead the US firm.
European off-patent industry association Medicines for Europe has appointed Arun Narayan as chair of its value-added medicines segment, taking over from Umberto Comberiati.
Private-equity firm Avista Capital Partners has struck a deal to acquire the extended topicals and dermatology business of privately-owned US company G&W Laboratories, which it plans to operate as G&W Dermatology under new chief executive officer Walt Kaczmarek.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.